Efficacy and Safety of SR1375 in Adult Patients With CAP

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a phase 2 study to evaluate the efficacy and safety of SR1375 in hospitalized adult patients with CAP. Patients will receive SR1375 or placebo for 8 weeks. The study duration for each patient is up to 10 weeks.
Epistemonikos ID: cf48ecb73950761e054a3cd51710049da6e16fdf
First added on: Sep 01, 2024